- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03613987
Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants
Randomized Control Trial: Synchronized Non-Invasive Positive Pressure Ventilation (sNIPPV) With Neurally-Assisted Ventilatory Assist (NAVA) Versus NIPPV in Extremely Low Birth Weight Infants
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypothesis:
The hypothesis is that sNIPPV will decrease the need for MVET and reduce BPD in ELBW infants as compared to NIPPV.
Specific Aims:
The specific aims are to determine whether:
- sNIPPV results in a decreased need for MVET at 7days of life and 28 days of life in ELBW infants compared to NIPPV.
- sNIPPV reduces BPD in ELBW infants compared to NIPPV. Research design and methods: ELBW infants will be enrolled in this study at the RNICU at MFCH of WMC following informed written parental consent.
Randomization:
ELBW infants will be randomized to either sNIPPV group or NIPPV group using a computer-generated scheme.
Extubation criteria:
- Infant is receiving caffeine.
Infants can be extubated at any point, but must be extubated following a 12-hour period of clinical stability when the ventilator settings have met all the following criteria:
- mean airway pressure (MAP) < 8cmH20,
- FiO2 < 0.4,
- pH > 7.2, and
- pCO2 < 70.
Intubation criteria:
Infants must be intubated if any of the following criteria occur:
- One apneic event requiring positive pressure ventilation (PPV).
- More than 6 apneic events requiring stimulation within a 6-hour period.
A deterioration in respiratory status as noted by any of the following criteria:
- pH < 7.2,
- pCO2 > 70,
- FiO2 > 0.6,
- Or, if in the opinion of the attending neonatologist, the baby is failing either non-invasive strategy.
Data Collection:
Demographic and outcome data will be collected from source data, and then the patient will be given a unique identifier, without reference to MRN or birthdate.
Tracheal aspirates will be collected per routine nursing care to look for inflammatory cytokine markers (IL8, IL6 and TNF alpha). This may help to determine if certain infants remained intubated due to a pro-inflammatory mechanism (if their TA cytokines were elevated early compared to those who may have been more successfully extubated because of low levels of cytokines).
During hospital stay, DNA and RNA samples will be extracted from buccal swabs, as certain babies are more susceptible to BPD based on their genetic foundations.
Charts will be reviewed to determine the duration of oxygen therapy as well as the duration of MVET.
MVET will be assessed at 7 days of life and 28 days of life as primary outcome. BPD, as defined as oxygen requirement at 36 weeks PMA, is a secondary outcome. Initial statistical analysis will be performed using chi square for categorical data; and t-test or Mann Whitney for continuous data that is normally or non-normally distributed (respectively), with statistical significance when P < 0.05.
Power analysis:
Based on the investigators' NICU data that NIPPV has MVET rate at 7 days of life of 84% for ELBWs, it was hypothesized that sNIPPV will decrease the need for MVET at 7 days of life by 40%. For a power of 80%, and an alpha value of 0.05, the sample size is 27 infants in each group. Anticipating a 10% dropout rate, this gives 30 as the sample size for each group.
Anticipated timeline:
With 80-100 ELBW infants admitted each year, enrollment is anticipated to be completed in 1 year.
The clinical implications of this study will determine if synchronized NIPPV in ELBW infants will reduce the need for mechanical ventilation and ultimately BPD.
There are no procedures, situations, or materials that will be hazardous to personnel. There are no courses planned which support the research training experience. This research will not include the use of experimental drugs or treatments.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shaili Amatya, MD
- Phone Number: 9144938558
- Email: shaili.amatya@wmchealth.org
Study Contact Backup
- Name: Lance Parton, MD
- Phone Number: 9144938558
- Email: Lance.parton@wmchealth.org
Study Locations
-
-
New York
-
Valhalla, New York, United States, 10595
- Westchester Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Babies born less than 1kg.
- Babies born at 24-30 weeks gestation.
Babies who qualify for surfactant administration within 90mins of birth:
- FiO2 > 0.4,
- nCPAP > 6, with
- Increased work of breathing as noted by grunting; and/or inter-, sub-, or supra-sternal retractions.
Exclusion Criteria:
- Babies with Grade 3-4 IVH (may not be known prior to randomization).
- Babies with congenital anomalies including neuromuscular disorder.
- Babies who do not require intubation until 7 days of life.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: NIPPV
non synchronized non invasive positive pressure ventilation
|
|
Experimental: NAVA-NIPPV
synchronized non invasive positive pressure ventilation with NAVA
|
Neurally adjust ventilator assist is used to synchronize the NIPPV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The need for Mechanical Ventilation via ET tube ( MVET) at 7 days of life
Time Frame: 7 days of life
|
Mechanical ventilation via Endotracheal tube
|
7 days of life
|
The need for Mechanical Ventilation via ET tube ( MVET) at 28 days of life
Time Frame: 28 days of life
|
Mechanical Ventilation via Endotracheal tube
|
28 days of life
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of BPD or need for supplemental O2 at 36 weeks corrected age
Time Frame: 36 weeks corrected gestational age
|
Bronchopulmonary Dysplasia
|
36 weeks corrected gestational age
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L12,175
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BPD - Bronchopulmonary Dysplasia
-
Adel MohamedHealth Sciences Centre, Winnipeg, Manitoba; Mount Sinai Hospital, CanadaCompletedBronchopulmonary Dysplasia (BPD)Canada
-
Cynthia McEvoyUniversity of Florida; University of California, San Francisco; Thrasher Research... and other collaboratorsCompletedBronchopulmonary Dysplasia (BPD)United States
-
Children's Hospital of Eastern OntarioThe Hospital for Sick Children; Hannover Medical School; MOUNT SINAI HOSPITAL; St... and other collaboratorsRecruitingLung Function | BPD - Bronchopulmonary DysplasiaCanada
-
PediatrixPhoenix Children's Hospital; Banner HealthActive, not recruitingBPD - Bronchopulmonary DysplasiaUnited States
-
University of FloridaCompletedPreterm Infant | Barotrauma | BPD - Bronchopulmonary DysplasiaUnited States
-
Jennifer ShepherdThe Gerber FoundationActive, not recruitingIntubation | Apnea of Prematurity | Hemodynamic Instability | BPD - Bronchopulmonary DysplasiaUnited States
-
Baystate Medical CenterRecruitingRespiratory Distress Syndrome, Newborn | Prematurity | BPD - Bronchopulmonary DysplasiaUnited States
-
Stanford UniversityCompletedHypertension, Pulmonary | Bronchopulmonary Dysplasia (BPD)United States
-
The Hospital for Sick ChildrenRecruitingPulmonary Hypertension | NEC | BPD - Bronchopulmonary DysplasiaCanada
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingRespiratory Distress Syndrome | Bronchopulmonary Dysplasia (BPD) | Prematurity; Extreme | NeonatalUnited States
Clinical Trials on NAVA technology to synchronize NIPPV
-
University of FloridaCompletedPreterm Infant | Barotrauma | BPD - Bronchopulmonary DysplasiaUnited States
-
King's College Hospital NHS TrustKing's College London; Guy's and St Thomas' NHS Foundation Trust; National Institute... and other collaboratorsCompletedAdults With Cardiopulmonary Disease at Risk of Prolonged Weaning From Mechanical VentilationUnited Kingdom
-
Women and Infants Hospital of Rhode IslandCompletedBronchopulmonary DysplasiaUnited States
-
Virginia Commonwealth UniversityTerminatedLow Birth Weight | Noninvasive VentilationUnited States
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI)RecruitingDeath | Bronchopulmonary Dysplasia | Extubation FailureUnited States, Canada
-
Arkansas Children's Hospital Research InstituteCompletedRespiratory Distress Syndrome, Newborn | Bronchopulmonary DysplasiaUnited States
-
University of Southern CaliforniaDey, L.P., Napa Valley, CalifoniaCompletedRespiratory Distress Syndrome, NewbornUnited States
-
King Fahad Armed Forces HospitalCompletedRespiratory Failure | Prematurity | Ventilator Lung; NewbornSaudi Arabia
-
Karolinska InstitutetResearch Institutes of Sweden (RISE)CompletedQuality of Life | mHealth | Mobile Applications | Lifestyle | AdultsSweden
-
Karolinska InstitutetRegion StockholmCompletedType 2 Diabetes Mellitus | ExerciseSweden